Radioactive 'Smart Bomb' drug tested in new leukemia treatment strategy
NCT ID NCT06802523
Summary
This early-stage study is testing a new three-drug combination for adults newly diagnosed with a serious blood cancer called acute myeloid leukemia (AML). The goal is to find a safe and effective dose. One drug is a targeted radioactive therapy designed to seek out and destroy cancer cells, while the other two help stop cancer growth and restore healthy blood cell production.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale University Cancer Center LAO
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.